Autonomic modulation and antiarrhythmic therapy in a model of long QT syndrome type 3

Larissa Fabritz 1, 2,*, Dierk Damke 1, Markus Emmerich 1, Susann G. Kaufmann 3, Kathrin Theis 1, Andreas Blana 1, Lisa Fortmüller 1, 2, Sandra Laakmann 1, 2, Sven Hermann 2, 4, Elena Aleyichenko 1, Johannes Steinfurt 1, Daniela Volkery 1, Burkhard Riemann 5, Uwe Kirchhefer 2, 6, Michael R. Franz 7, Günter Breithardt 1, Edward Carmeliet 8, Michael Schäfers 2, 4, Sebastian K.G. Maier 3, Peter Carmeliet 8, 9, and Paulus Kirchhof 1, 2

1Department of Cardiology and Angiology, University Hospital Münster, Albert-Schweitzer-Street 33, D-48129 Münster, Germany; 2Interdisciplinary Center for Clinical Research Münster (IZKF Münster), Münster, Germany; 3Medizinische Klinik und Poliklinik I, Universitätsklinikum Würzburg, Würzburg, Germany; 4European Institute of Molecular Imaging, University of Münster, Münster, Germany; 5Department of Nuclear Medicine, University Hospital Münster, Münster, Germany; 6Institute of Pharmacology and Toxicology, University Hospital Münster, Münster, Germany; 7Departments of Pharmacology and Cardiology, Georgetown University and VA Medical Center, Washington, DC, USA; 8Vesalius Research Center—KU Leuven, Leuven, Belgium; and 9Vesalius Research Center—VIB, Leuven, Belgium

* Corresponding author. Tel: +49 251 834 6034; fax: +49 251 834 7864. Email: fabritz@uni-muenster.de

Received 29 July 2009; revised 18 December 2009; accepted 22 January 2010; online publish-ahead-of-print 28 January 2010

Time for primary review: 22 days

Aims
Clinical observations in patients with long QT syndrome carrying sodium channel mutations (LQT3) suggest that bradycardia caused by parasympathetic stimulation may provoke torsades de pointes (TdP). β-Adrenoceptor blockers appear less effective in LQT3 than in other forms of the disease.

Methods and results
We studied effects of autonomic modulation on arrhythmias in vivo and in vitro and quantified sympathetic innervation by autoradiography in heterozygous mice with a knock-in deletion (∆KPQ) in the Scn5a gene coding for the cardiac sodium channel and increased late sodium current (LQT3 mice). Cholinergic stimulation by carbachol provoked bigemini and TdP in freely roaming LQT3 mice. No arrhythmias were provoked by physical stress, mental stress, isoproterenol, or atropine. In isolated, beating hearts, carbachol did not prolong action potentials per se, but caused bradycardia and rate-dependent action potential prolongation. The muscarinic inhibitor AFDX116 prevented effects of carbachol on heart rate and arrhythmias. β-Adrenoceptor stimulation suppressed arrhythmias, shortened rate-corrected action potential duration, increased rate, and minimized difference in late sodium current between genotypes. β-Adrenoceptor density was reduced in LQT3 hearts. Acute β-adrenoceptor blockade by esmolol, propranolol or chronic propranolol in vivo did not suppress arrhythmias. Chronic flecainide pre-treatment prevented arrhythmias (all P < 0.05).

Conclusion
Cholinergic stimulation provokes arrhythmias in this model of LQT3 by triggering bradycardia. β-Adrenoceptor density is reduced, and β-adrenoceptor blockade does not prevent arrhythmias. Sodium channel blockade and β-adrenoceptor stimulation suppress arrhythmias by shortening repolarization and minimizing difference in late sodium current.

Keywords
Long QT syndrome 3 • Antiarrhythmic therapy • Basic mechanisms of arrhythmias • Murine model • Telemetry ECG • Stress • Autoradiography

1. Introduction
Gain-of-function mutations in the cardiac sodium channel gene Scn5a can cause long QT syndrome 3 (LQT3) and arrhythmic death by torsades de pointes (TdP). In contrast to most patients carrying mutations in potassium channel genes, TdP and death occur predominantly during bradycardia, intermittent AV block, or sleep in LQT3 patients. While these observations may suggest that heightened...
parasympathetic tone can provoke TdP in LQT3, this has never been systematically studied.

β-Adrenoceptor-blockers, the standard first-line therapy in long QT syndrome patients, seem to be less efficacious in LQT3 in clinical observations.9 Sodium channel blockers are increasingly used as part of antiarrhythmic therapy in LQT3, mainly based on acute effects of such drugs in isolated cells and organs,10–12 and on a QT-shortening effect in LQT3 patients.13 The interaction between chronic sodium channel inhibition and autonomic triggers for arrhythmias in LQT3 has not yet been studied.

We therefore systematically studied effects of acute and chronic autonomic modulation in vivo and in vitro in heterozygous ΔKPQ-Scn5a knock-in mice with LQT3 (ΔKPQ-SCN5A).14,15

2. Methods

The investigation conforms with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85–23, revised 1996) and was approved by the local institutional review board (G61/99, G83/2004). Combination of chronic and acute pharmacologic interventions during telemetry is illustrated in Figure 1. Additional experiments were performed in isolated, beating hearts and isolated myocytes. Experiments and analyses performed in Munich, Germany, if not indicated otherwise. Chemicals used were from Sigma-Aldrich, 2-adrenoceptor-blocker esmolol 10–5 M (100 mg /10 mL, Baxter, Munich, Germany), or propranolol 1.7 × 10–4 M and 1.7 × 10–7 M applied in random order. Carbachol 10–7–10–5 M was applied in hearts without AV block.

2.1 Arrhythmias in freely roaming mice and during in vivo interventions

We implanted telemetric ECG transmitters (DSI, St Paul, MN, USA) and recorded telemetric ECGs during normal activity for 24 h, standardized swimming exercise, and repetitive warm air jet challenges17 at baseline, after 5 days of chronic β1-β2-adrenoceptor-blocker propranolol (propranololhydrochloride) 3.5 mg/day per os (p.o.) resulting in rate reduction and therapeutic plasma levels (77.5 ± 6.5 ng/mL)13 or after 10 days of sodium channel blocker flecainide treatment (50 mg/5 mL, MEDA Pharma, Bad Homburg, Germany), 45 mg/kg/day p.o., resulting in therapeutic plasma levels (509 ± 110 ng/mL), both applied orally via drinking water, mean fluid intake 7.1 ± 0.3 mL SD, or 0.2 mL/kg body weight (BW)/day (Figure 1). The cholinergic agonist carbachol (carbamylcholine chloride, 0.5 mg/kg intraperitoneally (i.p.)), the anticholinergic drug atropine (0.5 mg/kg i.p.), the antiarrhythmic agent AFDX116 (Tocris, Ellisville, MO, USA) at 5, 12.5, 25, 50 µg/kg BW i.p., and the β1-adrenergic catecholamine isoproterenol (isoproterenol hydrochloride 2 mg/kg i.p.) were applied separately.

Heart rate variability was calculated as the standard deviation of RR-intervals during periods of rest and exercise of at least 5 min.19,20

2.2 Electrophysiological study in isolated, beating hearts

A tissue bath ECG, and right and left ventricular monophasic action potentials (MAP) were simultaneously recorded from isolated, beating Langendorff-perfused hearts with mechanically induced AV block during spontaneous rhythm and pacing5,21 at baseline, after adding β1-β2-adrenoceptor-stimulator orciprenaline (1.7 × 10–6 M) with and without β1-β2-adrenoceptor-blocker esmolol 10–7–10–5 M (100 mg /10 mL, Baxter, Munich, Germany), or propranolol 1.7 × 10–4 M and 1.7 × 10–7 M applied in random order. Carbachol 10–7–10–5 M was applied in hearts without AV block.

2.3 Microautoradiography for cardiac β-adrenoceptors

After perfusion with modified Krebs–Henseleit solution,15,21 hearts were embedded in Tissue-Tek® (Sekura, Heppenheim, Germany) and frozen. Cryofixed hearts were sliced in short axis orientation (20 µm). For each heart, a pair of adjacent tissue sections was prepared. Microautoradiography was performed as described.12 Tissues were incubated in a buffer solution [50 nM HEPES, 5 mM MgCl2, 3% BSA, ph 7.4 (Roth, Karlsruhe, Germany)] for 10 min and dried. Tissues were then coated with solutions of radioactively labelled β-adrenoceptor antagonist 125I-ICYP (Perkin Elmer, Rodgau-Ju¨gesheim, Germany). A uniform radioligand concentration of 80 pM (approximately five times dissociation constant) was chosen to ensure a plateau in specific binding after 2 h of incubation.22,23 Tissues were washed in PBS (Intravet, Karlsruhe, Germany) and distilled water afterwards. To differentiate specific from unspecific binding, one of two slices was additionally incubated with an excess of unlabelled i-propranolol (10 µM). Microautoradiography was performed for 8 h using a high-resolution digital autoradiography system (Micro Imager, Biospace Lab, France). Short axis sections were analysed by manual segmentation of left ventricle using ImageJ (Rasband, National Institutes of Health, Bethesda, USA). Specific binding representing β-adrenoceptor density was calculated by subtraction of unspecific binding (125I-ICYP + Propranolol) from total tracer binding (125I-ICYP).

2.4 Whole-cell voltage clamp experiments in isolated ventricular cardiomyocytes

Peak and late sodium current was recorded at room temperature (22°C) at baseline and during β-adrenoceptor-stimulation with isoproterenol from rod-shaped, striated, and Ca2+-tolerant cells within 8 h of isolation using standard solutions and techniques.12,19,24 Currents were recorded with an HEKA-EPC 9 amplifier, and data were collected and analysed with PULSE (HEKA Elektronik, Lambrecht/Pfalz, Germany), Kaleidagraph 4.0 (Synergy, Reading, PA), and IGOR (WaveMetrics, Lake Oswego, OR) software. Isoproterenol (1.6 µM) diluted in external solution was applied with a motorstepper-controlled perfusion system. The holding

---

**Figure 1** In vivo study flow chart. Telemetry at baseline and during chronic pharmacological interventions (columns), baseline and acute in vivo stress tests and pharmacological modulation of the autonomic nervous system (rows). Additional experiments were performed ex vivo (functional studies, cellular electrophysiology, and autoradiography).
potential was \(-100\) mV, test pulse to 0 mV. Whole cell currents were recorded without pharmacological testing.

### 2.5 Statistical analyses

Paired and unpaired t-tests, univariate analysis of variance (ANOVA), and ANOVA analyses for multiple comparisons and repetitive measurements were used to compare continuous parameters (SPSS, version 12.0G for Windows). Fisher’s exact test was used to compare arrhythmia occurrence. Values are reported as mean ± SEM unless indicated otherwise. Differences were considered significant at a two-tailed alpha level of \(P < 0.05\) and marked by an asterisk (*) unless indicated otherwise.

### 3. Results

#### 3.1 \(\Delta\)KPQ-SCN5A mice show bradycardia and TdP-like arrhythmias during sleep

\(\Delta\)KPQ-SCN5A mice had more spontaneous pauses than WT littermate due to asystole or intermittent AV block during sleep (Figure 2A). 3/21 \(\Delta\)KPQ-SCN5A mice died spontaneously during long-term telemetric ECG monitoring showing extreme bradycardia (3/3) and TdP-like polymorphic ventricular arrhythmias (1/3) prior to death (Figure 2B). None of 17 WT died spontaneously during monitoring. Heart rate was lower in freely roaming \(\Delta\)KPQ-SCN5A mice compared with WT at rest and during stress (Table 1, Figure 2C).

#### 3.2 Stress in freely roaming \(\Delta\)KPQ-SCN5A mice does not provoke arrhythmias

Mental stress, exercise, \(\beta\)-adrenoceptor-stimulation (isoproterenol 2 mg/kg i.p.), or parasympathetic block by atropine (0.5 mg/kg i.p.) increased heart rate irrespective of genotype in freely roaming mice (Table 1). We never observed arrhythmias under these conditions. At high heart rate, QT intervals did not differ between genotypes, indicating alleviation of the long QT phenotype in vivo (Table 2). \(\Delta\)KPQ-SCN5A mice showed relative bradycardia compared with WT during physiological stress tests (Table 1).

#### 3.3 Cholinergic stimulation in vivo provokes arrhythmias in \(\Delta\)KPQ-SCN5A

Cholinergic stimulation with carbachol, a clinically used non-specific muscarinic and nicotinic agonist, aggravated bradycardia (0.5 mg/kg i.p. (approximately 0.275 \(\mu\)mol/kg), Table 1, Figures 2E, 3A and D), prolonged QT interval (Table 2, Figure 3C), and provoked bigemini or runs of TdP in \(\Delta\)KPQ-SCN5A mice (Figures 2E and 3). WT mice showed similar bradycardia after carbachol challenge, but only sporadic ventricular extrasystoles and neither bigemini nor TdP (Figure 3, Table 1). Atropine (0.5 mg/kg i.p.) prevented carbachol-induced bradycardia and related arrhythmias (n = 3/3 \(\Delta\)KPQ-SCN5A mice). The muscarinic receptor blocker AFDX116, 12.5, 25, or 50 \(\mu\)mol/kg BW, applied 15 min before carbachol, abolished the effect of carbachol and prevented arrhythmias in n = 3/3 \(\Delta\)KPQ-SCN5A mice (Figure 3D, see Supplementary material online, Figure S2).

#### 3.4 Chronic \(\beta\)-adrenoceptor-blockade does not prevent carbachol-induced arrhythmias in vivo

Chronic propranolol therapy reduced heart rate, heart rate variability, and heart rate increase during 24 h monitoring, swimming, and mental stress in freely roaming WT and \(\Delta\)KPQ-SCN5A mice (Figure 2D, Table 1). Chronic propranolol therapy (3.5 mg/day) did not prevent carbachol-provoked arrhythmias (8/12 TdP or bigemini in \(\Delta\)KPQ-SCN5A with propranolol *vs. 0/9 WT, Figure 3, Table 1). However, care had to be taken to keep animals in a stressless environment during cholinergic stimulation because physical or mental activation of animals resulted in cessation of arrhythmias.

#### 3.5 Carbachol provokes bigemini and TdP in isolated \(\Delta\)KPQ-SCN5A hearts

Carbachol perfusion caused similar effects on the isolated heart as in vivo, i.e. bradycardia, bigemini, and TdP. Cycle length was 739 ± 171 ms during carbachol 10\(^{-7}\) M; 1128 ± 310 ms during carbachol 10\(^{-6}\) M (*vs. 234 ± 17 ms baseline). Bigemini occurred in 33/42 and TdP in 13/42 \(\Delta\)KPQ-SCN5A hearts during carbachol (*vs. 22/42 bigemini and 4/42 TdP at baseline, Figure 4A). Carbachol neither induced arrhythmias nor prolonged APD during controlled rates (Supplementary material online, Table), but increased spontaneous APD by decreasing heart rate in \(\Delta\)KPQ-SCN5A hearts (APD90: baseline 45 ± 2 ms, carbachol 10\(^{-7}\) M 64 ± 7 ms, carbachol 10\(^{-6}\) M 87 ± 7 ms, *vs. baseline and *vs. WT, Figure 4B and C).

#### 3.6 \(\beta\)-Adrenoceptor-blockade impairs antiarrhythmic effects of catecholamines and can prolong ventricular action potentials in isolated hearts from \(\Delta\)KPQ-SCN5A mice

\(\beta\)-Adrenoceptor-stimulation by orciprenaline (1.7 \(\mu\)M) completely prevented and suppressed EADs and TdP in isolated hearts with mechanical AV block (0/16 \(\Delta\)KPQ-SCN5A hearts *vs. baseline 4/13, Figure 5A and B). Orciprenaline shortened ventricular APD (Figure 6A and B) and decreased APD dispersion at paced cycle lengths of 200 and 300 ms (orciprenaline 9 ± 1 ms vs. baseline 19 ± 2 ms). Propranolol (1.7 × 10\(^{-6}\) M and 1.7 × 10\(^{-7}\) M) did not prolong APD in \(\Delta\)KPQ-SCN5A hearts (data not shown). Co-infusion of esmolol and orciprenaline rendered APD similar to baseline values in WT (+9% APD), but caused prolongation of APD and dispersion of APD up to 25% above baseline values in \(\Delta\)KPQ-SCN5A hearts (P < 0.05, Figure 6B). Orciprenaline lost its antiarrhythmic effect in the presence of propranolol or esmolol (Figure 5B). Propranolol slowed intrinsic ventricular rhythm after AV block even in presence of equimolar orciprenaline, and complete asystole was more frequent (5/12 \(\Delta\)KPQ-SCN5A hearts, *vs. baseline 1/27). Propranolol alone (1.7 × 10\(^{-6}\) M) suppressed EADs and TdP in hearts with mechanical AV block, but caused bradycardia with temporary loss of ventricular rhythm in 4/4 \(\Delta\)KPQ-SCN5A isolated hearts. Orciprenaline caused accelerated regular ventricular rhythms in all isolated hearts.

#### 3.7 Decreased \(\beta\)-adrenoceptor density in \(\Delta\)KPQ-SCN5A

\(\beta\)-Adrenoceptor density as measured by quantitative microautoradiography was markedly decreased in \(\Delta\)KPQ-SCN5A vs. WT hearts (Figure 6C).
Figure 2  Illustrations of intrinsic bradycardia and arrhythmias in ΔKPQ-SCN5A mice. (A) Telemetric ECG of pauses and atrioventricular block in unrestrained ΔKPQ-SCN5A mice. (B) Bradycardia-induced lethal torsades de pointes storm in an unrestrained ΔKPQ-SCN5A mouse. Within 30 min, 21 torsades de pointes episodes (duration 10 s–min) occurred. (C) Heart rate in unrestrained ΔKPQ-SCN5A and littermate WT mice during 24 h monitoring (mean ± SEM). ΔKPQ-SCN5A were bradycardic. (D) Propranolol decreased heart rates and blunted changes between rest during the day and activity at night and between genotypes. (E) Carbachol-induced episode of bradycardia with intermittent bigemini and torsades de pointes like arrhythmias in a ΔKPQ-SCN5A mouse.
Table 1  Heart rate, sinus pauses, and AV block in unrestrained mice at baseline and effect of acute and chronic interventions

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>ΔKPQ-SCN5A</th>
<th>Propranolol</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>WT</td>
<td>ΔKPQ-SCN5A</td>
<td>WT</td>
</tr>
<tr>
<td>Mean heart rate (HR) 24 h</td>
<td>548 ± 47(16)</td>
<td>498 ± 52(18)</td>
<td>489 ± 33***(13)</td>
</tr>
<tr>
<td>HR variability SD-HR</td>
<td>76 ± 15(16)</td>
<td>86 ± 15(18)</td>
<td>57 ± 13***(13)</td>
</tr>
<tr>
<td>HR 10 am - 6 pm (at rest)</td>
<td>505 ± 20**(16)</td>
<td>451 ± 24***(18)</td>
<td>464 ± 20***(13)</td>
</tr>
<tr>
<td>HR carbachol i.p.</td>
<td>675 ± 35**(10)</td>
<td>677 ± 22***(13)</td>
<td>555 ± 54***(10)</td>
</tr>
<tr>
<td>HR air jet stress</td>
<td>678 ± 35**(10)</td>
<td>640 ± 44***(13)</td>
<td>583 ± 37***(10)</td>
</tr>
<tr>
<td>HR isoproterenol i.p.</td>
<td>725 ± 41**(11)</td>
<td>694 ± 35***(14)</td>
<td>699 ± 71***(4)</td>
</tr>
<tr>
<td>HR atropine i.p.</td>
<td>641 ± 42**(3)</td>
<td>612 ± 68***(6)</td>
<td>no value</td>
</tr>
<tr>
<td>HR carbachol i.p.</td>
<td>223 ± 38**(7)</td>
<td>230 ± 51**(9)</td>
<td>190 ± 21**(4)</td>
</tr>
<tr>
<td>AVB or pauses/5 min/24 h</td>
<td>1.4 ± 1.3(6)</td>
<td>3.1 ± 1.8**(6)</td>
<td>1.7 ± 1.4(6)</td>
</tr>
<tr>
<td>Max pause (ms cycle length)</td>
<td>227(6)</td>
<td>601(6)</td>
<td>489(5)</td>
</tr>
</tbody>
</table>

Table 2  ECG parameters in unrestrained ΔKPQ-SCN5A and WT mice

<table>
<thead>
<tr>
<th></th>
<th>PQ duration (ms)</th>
<th>QT interval (ms)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>WT</td>
<td>ΔKPQ-SCN5A</td>
</tr>
<tr>
<td>Baseline 600 b.p.m.</td>
<td>32.5 ± 0.7</td>
<td>32.6 ± 0.6</td>
</tr>
<tr>
<td>450 b.p.m.</td>
<td>34.7 ± 0.6</td>
<td>35.8 ± 0.6</td>
</tr>
<tr>
<td>n</td>
<td>13(13)</td>
<td>23(23)</td>
</tr>
<tr>
<td>Propranolol 600 b.p.m.</td>
<td>29.7 ± 1.0**</td>
<td>32.6 ± 0.5*</td>
</tr>
<tr>
<td>450 b.p.m.</td>
<td>32.1 ± 1.2</td>
<td>35.1 ± 0.7*</td>
</tr>
<tr>
<td>n</td>
<td>5(5)</td>
<td>11(11)</td>
</tr>
<tr>
<td>Carbachol i.p. mono 200 b.p.m.</td>
<td>33.4 ± 0.9</td>
<td>38.3 ± 0.9*</td>
</tr>
<tr>
<td>n</td>
<td>14(10)</td>
<td>18(16)</td>
</tr>
<tr>
<td>Carbachol i.p. +propranolol 200 b.p.m.</td>
<td>36.3 ± 3.1</td>
<td>37.4 ± 1.2</td>
</tr>
<tr>
<td>n</td>
<td>5(4)</td>
<td>7(5)</td>
</tr>
<tr>
<td>Carbachol i.p. + flecainide 200 b.p.m.</td>
<td>38.9 ± 1.5**</td>
<td>44.2 ± 2.7**</td>
</tr>
<tr>
<td>n</td>
<td>7(4)</td>
<td>7(4)</td>
</tr>
<tr>
<td>Isoproterenol i.p. 700 b.p.m.</td>
<td>29.9 ± 0.5</td>
<td>31.5 ± 0.7</td>
</tr>
<tr>
<td>n</td>
<td>9(7)</td>
<td>14(12)</td>
</tr>
<tr>
<td>Swim stress 700 b.p.m.</td>
<td>30.2 ± 1.8</td>
<td>26.5 ± 2.3</td>
</tr>
<tr>
<td>n</td>
<td>3(3)</td>
<td>5(5)</td>
</tr>
<tr>
<td>Air jet stress 700 b.p.m.</td>
<td>29.7 ± 0.5</td>
<td>29.3 ± 1.7</td>
</tr>
<tr>
<td>n</td>
<td>3(3)</td>
<td>5(5)</td>
</tr>
</tbody>
</table>

Mean ± SD of heart rates (n of mice in brackets) in unrestrained ΔKPQ-SCN5A and littermate WT mice at baseline and during chronic oral propranolol treatment. Pauses or AV block numbers were determined as mean of 24 5-min-time periods over 24 consecutive hours per animal.

b.p.m., beats per minute; HR, variability SD-HR standard deviation of heart rate; i.p., intraperitoneal (time 2–12 min after i.p. injection was analysed, only sinus beats counted); ES, extrastyle (10 beats prior to first ES or arrhythmia analysed); AVB, ativoventricular block.

*P < 0.05 ΔKPQ-SCN5A vs. WT.

**P < 0.05 heart rate vs. respective 24 h heart rate.

***P < 0.05 baseline vs. propranolol.

3.8 β-Adrenoceptor-stimulation blunts the difference in INa, late between ΔKPQ-SCN5A and WT cardiomyocytes

Late sodium current (INa, late) was increased in ΔKPQ-SCN5A cardiomyocytes (Figure 7). Peak (early) sodium current densities did not differ between groups under both conditions (P = ns, Figure 7). Isoproterenol (10^-6 M superfusion) increased INa, late in both genotypes. INa, late was not different between genotypes during adrenergic stimulation (*vs. baseline; P = ns for ΔKPQ-SCN5A vs. WT) due to a higher relative increase of INa, late in WT cells compared with ΔKPQ-SCN5A (increase in INa, late in ΔKPQ-SCN5A 49 ± 10%, WT 90 ± 24%, Figure 7).
Figure 3  Effect of carbachol on ECG morphology and arrhythmias in unrestrained ΔKPQ-SCN5A mice with and without chronic propranolol or flecainide treatment. (A) Representative telemetry ECG recordings at baseline and during carbachol challenge with and without chronic propranolol or flecainide treatment in unrestrained ΔKPQ-SCN5A mice. (B) Bar graphs give numbers of experiments with arrhythmias (filled bars, one to three challenges per animal) and without arrhythmias (open bars) in both genotypes. Carbachol induced arrhythmias in ΔKPQ-SCN5A mice only. Chronic flecainide prevented arrhythmias, chronic propranolol did not (all \( P < 0.05 \)). (C) QT interval in unrestrained ΔKPQ-SCN5A and littermate WT mice. Tele-electrocardiographic summary potentials selected from spontaneous frequencies during heart rates at baseline (600 b.p.m, 450 b.p.m), and low (200 b.p.m) heart rates after carbachol challenge with or without chronic flecainide therapy. Carbachol-induced bradycardia exacerbated QT prolongation in ΔKPQ-SCN5A, (values and animal numbers in Table 2).
3.9 Chronic flecainide therapy prevents arrhythmias induced by cholinergic stimulation in freely roaming ΔKPQ-SCN5A mice

Chronic flecainide (45 mg/kg BW/day) did not prevent carbachol-induced bradycardia (WT 223 ± 33 b.p.m., vs. ΔKPQ-SCN5A 203 ± 17 b.p.m., P = ns vs. WT, P < 0.05 vs. baseline), but prevented carbachol-induced arrhythmias in unrestrained ΔKPQ-SCN5A mice (Tdp or bigemini in 0/11 carbachol challenges, P < 0.05 vs. in 7/11 in the same mice without flecainide, Figure 3).

4. Discussion

This systematic study of interactions of chronic and acute autonomic modulation and sodium channel blockade identified several new findings in this model of LQT3:

(1) Cholinergic stimulation provokes bradycardia and arrhythmias in vivo in this model of LQT3.

(2) Stress and catecholamines suppress arrhythmias in vivo and shorten ventricular action potentials in this model. \( h_{Na, late} \) in ΔKPQ-SCN5A myocytes is relatively insensitive to β-adrenergic stimulation.

(3) β-Adrenoceptor-blockade does not prevent arrhythmias, but blunts the antiarrhythmic effects of catecholamines, and prolongs repolarization in vivo and in vitro in this model.

(4) Cardiac β-adrenoceptor expression is markedly reduced in this model of LQT3.

(5) Chronic pharmacological inhibition of sodium currents by flecainide prevents arrhythmias in vivo in this model of LQT3.

Within the limitations of a preclinical study, and taken together with other studies in isolated hearts or in cellular preparations,\(^{12,25-29}\) our data confirm the clinical observation that patients carrying sodium channel mutations do not benefit from β-adrenoceptor-blocker therapy. Cholinergic stimulation appears proarrhythmic in patients carrying this mutation or SCN5A mutations with similar biophysical characteristics. Finally, our data show that chronic sodium channel inhibition by flecainide can prevent arrhythmias in freely roaming animals, thereby extending the existing data on sodium channel blockade in cells and isolated organs.\(^{12,25,26,29}\)
4.1 Cholinergic stimulation is highly arrhythmogenic in this model of LQT3

Cholinergic stimulation had a marked proarrhythmic effect showing TdP after bradycardia and QT prolongation in LQT3 in vivo. This is consistent with observations in patients with LQT3 and may be mediated by bradycardia and the unique kinetics of the increased \( I_{Na, \text{late}} \) in the \( \Delta KPQ \) mutant. \( I_{Na, \text{late}} \) is more pronounced at low heart rates in \( \Delta KPQ-\text{SCN5A} \). These biophysical properties of the mutated sodium channel can also explain excessive prolongation of QT interval in response to bradycardia at rest, and a shortening of repolarization during sinus tachycardia in freely roaming \( \Delta KPQ-\text{SCN5A} \) mice in this study. Effects of carbachol on cardiac electrophysiology are predominantly mediated by muscarinic receptors, most of them of the M2 subtype, and muscarinic stimulation does no longer cause bradycardia in M2y2 mutant mice. Carbachol-induced arrhythmias were no longer observed if either atropine or the muscarinic antagonist AFDX116 was co-applied, suggesting that muscarinic and preferential M2 activation mediated the proarrhythmic effect of carbachol in this model.

4.2 Sympathetic stimulation suppresses and prevents arrhythmias in \( \Delta KPQ-\text{SCN5A} \)

Endogenous catecholamines shortened QT interval and prevented arrhythmias in unrestrained \( \Delta KPQ-\text{SCN5A} \) mice, and even
interrupted arrhythmias induced by cholinergic stimulation in vivo.  
β-Adrenoceptor-stimulation completely suppressed TdP in the intact, beating heart, consistent with reports in transgenic and pharmacological models of LQT3, and reduced the difference of late sodium current between WT and ΔKPQ-SCN5A cardiomyocytes.

β-Adrenoceptor-stimulation can affect sodium currents by PKA-dependent and PKA-independent mechanisms: PKA phosphorylates cardiac sodium channels, and sodium channels can directly bind to β-adrenoceptors in conjunction with G-protein α-units. Activation of α1-adrenoceptors can activate protein kinase C and alter sodium current. α1-Adrenoceptor activation can inhibit sodium channel bursting via protein kinase C in ΔKPQ-SCN5A mutant cardiomyocytes. Multiple effects have been seen in expression systems, e.g. in another model of LQT3 using PKA stimulation in transfected HEK293 cells. The known effects of β-adrenoceptor stimulation on repolarizing channels may be responsible for catecholamine-induced action potential shortening in WT and ΔKPQ-SCN5A hearts, as their expression is not altered in ΔKPQ-SCN5A hearts (RNA of KCNQ1 and KCNE1 encoding I\(_{Ks}\), MERG1B encoding I\(_{Kr}\), Kv1.4, Kv4.2, and Kv4.3 encoding I\(_{to}\), and Kv1.5 encoding I\(_{Ks\text{slow}}\)).

### 4.3 β-Adrenoceptor-blockade inhibits beneficial catecholamine-effects in ΔKPQ-SCN5A

Chronic β-adrenoceptor-blocker therapy prevented antiarrhythmic effects of physical stress or catecholamines in freely roaming ΔKPQ

---

**Figure 5** Antiarrhythmic effect of β-adrenoceptor stimulation in isolated beating hearts. (A) Representative recording of two simultaneous monophasic action potentials (MAP) and ECG during afterdepolarizations and short torsades de pointes (TdP) episodes at baseline after AV block (top left). TdP are suppressed by β-adrenoceptor stimulation (orquiprenaline, top right). Ectopy reappears during co-infusion of orquiprenaline and β-adrenoceptor-blocker esmolol, and pause-triggered TdP occurs during infusion of esmolol alone. (B) Number of ΔKPQ-SCN5A hearts with arrhythmias at baseline, with β-adrenoceptor-blockers, during co-infusion of β-adrenoceptor-blockers and orquiprenaline, and with orquiprenaline alone; *P < 0.05 vs. baseline (number of hearts depicted as columns).
Figure 6 β-Adrenoceptors and autonomic modulation. (A) Representative monophasic action potential recordings at a pacing cycle length of 200 ms in isolated, beating hearts after mechanical AV block. (B) Mean action potential durations during fixfrequent pacing at baseline, during infusion of esmolol $1.7 \times 10^{-6}$ M, orciprenaline $1.6 \times 10^{-6}$ M; and orciprenaline $1.6 \times 10^{-6}$ M plus esmolol $1.7 \times 10^{-6}$ M. Mean of 19–33 action potentials from 10 to 11 WT hearts and 11 to 31 action potentials from 10 to 12 ΔKPQ-SCN5A hearts. At long cycle lengths, number of action potentials was reduced to five WT, seven ΔKPQ-SCN5A, due to fast intrinsic heart rates. (C) β-Adrenoceptor binding was decreased in ΔKPQ-SCN5A mouse hearts. Specific binding of $^{125}$I-ICYP to β-adrenoceptors on cryofixed myocardial short axis sections in $n = 4–5$ per genotype. Binding is expressed as counts/min/mm$^2$. Inset shows examples of total ICYP and non-specific binding in two representative hearts.
mice and β-adrenoceptor-blocker treatment did not prevent arrhythmias, consistent with observations in LQT3 patients (Table 1 and 2, Figure 3 and 525, Supplementary material online, Figure S3).4,44 – 46 β-Adrenoceptor-blockade by esmolol caused lengthening of ventricular action potentials (Figure 6). These observations suggest that β-adrenoceptor-blockers may not only blunt the beneficial effects of catecholamines on ventricular action potential duration and QT interval in vivo, but inhibit beneficial effects of ‘endogenous’ catecholamines in the heart, e.g. stemming from spontaneous release and incomplete re-uptake of sympathetic granules from sympathetic nerve endings.

4.4 Reduced β-adrenoceptor density

Reduced cardiac β-adrenoceptor density was found in this model (Figure 6C). Although up to date, little is known about β-adrenoceptor density in LQT3 patients, reduced β-adrenoceptor density was found in symptomatic patients with arrhythmogenic right ventricular cardiomyopathy.47 As there may be phenotypic variations in patients with SCN5A mutations ('overlap syndromes'), our observations warrant studies of β-adrenoceptor density in LQT3 patients. Reduction of β-adrenoceptor binding may add another explanation why β-adrenoceptor-blockers did not prevent ventricular arrhythmias in ΔKPQ-SCN5A mice. Reduced β-adrenoceptor expression in structurally and functionally normal LQT3 hearts invites further study.

4.5 Antiarrhythmic effects of chronic flecainide therapy in vivo

Marked β-adrenoceptor-blocker-induced action potential prolongation was blunted when propranolol, a β-adrenoceptor-blocker that is also a weak sodium channel blocker,48 was used. Long-term sodium channel blockade by flecainide completely prevented spontaneous and carbachol-induced arrhythmias in this study, thereby extending prior reports of acute effects of sodium channel blockade in vitro in this model11,14,15 and in another model of LQT349 to beneficial effects of chronic therapy. Our observation of beneficial effects of chronic sodium channel inhibition in vivo is consistent with clinical observation.5 Prevention of arrhythmias by sodium channel block confirms that abnormal late sodium current is required for arrhythmias in this LQT3 model in vivo, and supports the notion that inhibition of late sodium current may be effective in LQT3, in contrast to β-adrenoceptor-blockade. In addition to sodium current blockade, flecainide has parasympatholytic effects. This might be considered as an additional potential antiarrhythmic effect warranting future study.

4.6 Limitations and potential clinical implications

Afterdepolarizations and triggered beats can be difficult to verify in MAP even if recording quality is high and standardized. In vivo or
in-organ mapping techniques may confirm the role of afterdepolarizations and triggered beats in this model in the future. Our findings on sodium currents are in accordance with experiments from Fredj et al.\textsuperscript{12} which showed a difference in late sodium current while peak currents where not altered. Nuyens et al.\textsuperscript{14} reported a higher peak sodium current in the LQT3 model at high frequencies (10 Hz).

Cholinergic stimulation had arrhythmogenic effects in vivo and in the isolated heart in \( \Delta KPQ-SCN5A \), suggesting that parasympathetic agents such as atropine may be antiarrhythmic in LQT3. Comparable to the findings reported here, sinus bradycardia, spontaneous pauses, and atrioventricular block (see Supplementary material online, Figure S3) were observed in patients with LQT3.\textsuperscript{4,50} Bradycardia in LQT3 may be due to altered inactivation kinetics in the sinus node,\textsuperscript{51} and/or to electrotonic modulation of sinus nodal firing by surrounding cells. This warrants further study.

Electrical storm in patients with Brugada syndrome has been successfully treated with \( \beta \)-mimetic agents (e.g. isoproterenol) or quinidine, whereas parasympathetic stimulation and \( \beta \)-adrenoceptor-blockade may provoke arrhythmias in Brugada syndrome. It is conceivable that some of the pathophysiological mechanisms observed here may also apply to selected patients with a Brugada ECG pattern, sodium channel mutation, and ‘overlap syndromes’ although biophysical properties of SCN5A mutations found in Brugada syndrome usually cause loss-of-function.

Chronic sodium channel blockade suppressed spontaneous and carbachol-induced arrhythmias in vivo and in the beating heart in this model of LQT3. Our findings may apply to other forms of LQT3.\textsuperscript{50} Within the limitations of a preclinical study, our data provide another rationale for genetic testing and clinical alertness\textsuperscript{7} in LQT patients to identify those with sodium channel mutations, in order to start or maintain sodium channel blocker therapy.\textsuperscript{13,52} Conduction slowing and aggravation of bradycardia by sodium channel blocking drugs must be considered.\textsuperscript{53–55} More selective inhibitors of the \( \mathrm{Na}^+ \) current like mexiletine or ranolazine may be considered in LQT3 patients at risk of arrhythmias due to conduction slowing.

These preclinical findings cannot be directly transferred to clinical situations noting differences between mice and men. Nonetheless, reduced \( \beta \)-adrenoceptor density, prolongation of ventricular action potentials by esmolol, and lack of antiarrhythmic effects of \( \beta \)-adrenoceptor-blockers in vivo caution use of \( \beta \)-adrenoceptor-blockers in LQT3, especially when published reports in this model are considered, and suggest that catecholamines may have acute antiarrhythmic effects in this model, if only by increasing rate.\textsuperscript{11,12,14,25,29,32,37}

**Supplementary material**

Supplementary material is available at Cardiovascular Research online.

**Acknowledgements**

We thank Nina Kreienkamp, Marcel Tekook, Peter Kahr, Christoph Waldeyer, Ilaria Piccini, Jenny Muck, and Sandra Schröer for excellent technical assistance, and Tonja Fabritz for artwork.

**Conflict of interest** none declared except for the fact that flecainide plasma levels were measured free of charge by MEDA Pharma.

**Funding** This work was supported by: Medical Faculty, University of Münster, ‘Innovative Medical Research’ [IMF FA120431 to L.F., PK]; Deutsche Forschungsgemeinschaft DFG [FA 413-3/1 to L.F., Ki/731/1-1 to PK., Ma 2252 to S.K.G.M., SFB 656 MobIl AS to B.R., PK; A8 to L.F., PK; C1 to G.B., Z5 to B.R.]; Interdisciplinary Centre for Clinical Research IZKF Münster [Ki/1/2007/07 U.K., L.F.; core units CarTel to PK., SmAP to M.S.], and Fondation Leducq [ENAFRA 07CV003 to PK.]. Funding to pay the open access publication charge was provided by DFG FA 413/3-1 and SFB MobIl.

**References**


